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Abstract
Rationale—Nicotine and alcohol co-use is highly prevalent, and as such, individuals experience 
the interoceptive effects of both substances together. Therefore, examining sensitivity to a 
compound nicotine and alcohol (N+A) interoceptive cue is critical to broaden our understanding of 
mechanisms that may contribute to nicotine and alcohol co-use.
Objectives—This work assessed the ability of a N+A interoceptive cue to gain control over 
goaltracking behavior and determined the effects of the α4β2 nicotinic partial agonist and 
smoking cessation compound varenicline on sensitivity to N+A.
Methods—Two groups of male Long-Evans rats were trained to discriminate N+A (0.4 mg/kg 
nicotine + 1 g/kg alcohol, IG) from water under two different training conditions using a Pavlovian 
drug discrimination task. The effects of varenicline (0, 1, 3 mg/kg, IP) administered alone and on 
sensitivity to N+A and the components were determined.
Results—Under both training conditions, N+A rapidly gained control over behavior, with a 
greater contribution of nicotine to the N+A compound cue. Varenicline fully substituted for the N
+A training dose and varenicline (1 mg/kg) enhanced sensitivity to the lowest N+A dose (0.1N
+0.1A). Given the high selectivity of varenicline for the α4β2 receptor, this finding suggests a 
functional role for α4β2 nicotinic acetylcholine receptors (nAChR) in modulating sensitivity to N
+A.
Conclusions—The N+A compound cue is a unique cue that is modulated in part, by activity at 
the α4β2 nAChR. These findings advance understanding of the interoceptive effects of nicotine 
and alcohol in combination and may have implications in relation to their co-use.
Introduction
Combined nicotine and alcohol co-abuse constitutes a world-wide health risk. Considering 
the health risks of excessive alcohol use or smoking, it is not surprising that in combination, 
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negative patient outcomes and mortality rates increase substantially (Hurt et al. 1996; 
Schmidt and Popham 1981). Moreover, given the frequency with which nicotine and alcohol 
are used in combination, it is important to consider that individuals often experience the 
interoceptive effects of both substances together (i.e., a unique compound interoceptive cue). 
Indeed, preclinical work using operant drug discrimination models has shown that a 
compound nicotine+alcohol interoceptive cue can serve as a discriminative stimulus to 
modulate behavior (Ford et al. 2013; Ford et al. 2012; Gauvin and Holloway 1993; Troisi et 
al. 2013).
In the present work, we sought to examine if a compound nicotine+alcohol interoceptive 
drug state could gain control of reward-seeking behavior using a Pavlovian drug 
discrimination procedure. Under such procedures, the drug state (e.g., nicotine+alcohol) sets 
the occasion for when the offset of an environmental stimulus (e.g., light) is followed by a 
reward (e.g., sucrose). On intervening vehicle training days, light offset is not followed by 
sucrose delivery. Consequently, the drug state comes to modulate behavior as evidenced by 
increased anticipatory reward-seeking during the cue light (i.e., head entries into a liquid 
receptacle; “goal-tracking”) on drug training sessions. These procedures have been used to 
characterize the interoceptive effects of several drugs including alcohol, amphetamine, 
caffeine, methamphetamine, and nicotine (Besheer et al. 2012; Murray et al. 2007; Palmatier 
et al. 2004; Palmatier et al. 2005; Reichel et al. 2007). Furthermore, the opposite association 
can also be trained, such that the drug state can signal the absence of reward (i.e., assessment 
of subject’s ability to withhold behavior). Together, these procedures provide Feature 
Positive (FP) and Feature Negative (FN) training conditions, respectively, producing a 
powerful complimentary assessment of drug-state control over behavior, as different 
behavioral and neurobiological mechanisms are likely recruited. For example, FP conditions 
are thought to be driven by a direct excitatory link to the conditioned stimulus, whereas FN 
conditions are thought to be driven by an activation of context-specific inhibitory processes 
(see Bouton 1998 for review). Therefore, the primary goal of the present work was to 
determine whether a nicotine+alcohol interoceptive cue could be trained to control 
discriminated goal-tracking behavior under FP and FN conditions in male Long Evans rats 
and the relative contribution of each component of the nicotine+alcohol cue under both 
training conditions. Based on the operant drug-discrimination literature, it was hypothesized 
that the alcohol component would have a greater control over goal-tracking behavior than 
the nicotine component (Ford et al. 2012).
In addition, there has been growing interest in the smoking cessation agent varenicline 
(VAR; Chantix), a partial agonist of α4β2 nicotinic acetylcholine receptors (nAChR), for the 
treatment of alcohol use disorders. The α4β2 receptor accounts for 90% of the high-affinity 
nicotine binding sites in the mammalian brain and is largely expressed in the prefrontal 
cortex, nucleus accumbens core and ventral tegmental area, brain regions important in 
associative learning and drug abuse (Chatterjee and Bartlett 2010; Colombo et al. 2013; 
Dineley et al. 2015; Everitt et al. 1999; Millar and Harkness 2008). Importantly, VAR has 
been shown to be significantly more selective for the α4β2 receptor compared to the α3β4, 
α1 and α7 receptors (Coe et al. 2005). In clinical studies, VAR has been shown to decrease 
alcohol consumption in heavy drinking smokers (Fucito et al. 2011; Mitchell et al. 2012). 
Therefore, another goal of the present work was to assess the effects of VAR pretreatment 
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on: 1) sensitivity to the nicotine+alcohol interoceptive cue, 2) sensitivity to each component, 
and 3) to determine whether VAR has stimulus effects similar to the nicotine+alcohol cue 
when administered alone. Considering evidence that the alcohol component overshadows the 
nicotine component (Ford et al. 2012), and recent findings showing decreased sensitivity to 
alcohol following VAR pretreatment (Randall et al. 2015), it was hypothesized that VAR 
would decrease sensitivity to the compound cue and that this may be related specifically to 
decreased sensitivity to the alcohol component. Given that VAR has been shown to partially 
substitute for nicotine (i.e., have some nicotine-like effects) as assessed in operant 
discrimination procedures (LeSage et al. 2009; Paterson et al. 2010), it was hypothesized 
that similar results would be observed when VAR was administered alone and that VAR 
would potentiate sensitivity to the nicotine component.
Materials and Methods
Animals
Male Long Evans rats (Harlan Sprague Dawley, Indianapolis, IN) weighing 250-275 g upon 
arrival to the colony were individually housed in ventilated cages. Rats were handled and 
weighed daily for one week before training began. Rats were fed daily for the duration of the 
study such that weights maintained at approximately 325-340 g. Water was available 
continuously in the home cage. The colony room was maintained on a 12-h light/dark cycle 
and experiments were conducted during the light portion of the cycle. Animals were under 
continuous care and monitoring by veterinary staff from the Division of Laboratory Animal 
Medicine (DLAM) at UNC-Chapel Hill. All procedures were also carried out in accordance 
with the NIH Guide to Care and Use of Laboratory Animals and institutional guidelines. 
UNC-Chapel Hill is accredited by the Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC).
Pavlovian Drug Discrimination Training and Testing Procedures
Sucrose Access Training—Rats were trained using the same behavioral chambers and 
procedures were similar to those described in detail in (Besheer et al. 2012). Additionally, 
chambers were outfitted with infrared photobeams (that divided the chamber into 4 parallel 
zones) to measure locomotor activity during sessions (number of beam breaks). Briefly, rats 
had three 50-min sessions in which 26% sucrose (w/v) was randomly presented across the 
session to train rats to approach the liquid receptacle. The probability of sucrose presentation 
decreased from the first to the last session and by the last 10 min of the final session rats 
received ~0.75 sucrose presentations/min.
Discrimination Acquisition Training—Training sessions were 5 days per week (M-F) 
during which a nicotine (0.4 mg/kg) + alcohol (1 g/kg) mixture (N+A) or water was 
administered by intragastric gavage (IG) prior to the start of the sessions. Immediately 
following N+A or water administration the rats were placed in the chambers. During this 
time no cue lights were illuminated, no sucrose was presented and head entries into the 
liquid receptacle were not recorded. The 15-min session began after this 10-min delay. 
Therefore, based on the existing literature the 10 min delay represents a time point that 
likely corresponds to the ascending limb of plasma/blood and brain alcohol and nicotine 
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levels following oral administration (Alsharari et al. 2014; Matta et al. 2007; Quertemont et 
al. 2003; Turner 1975). For the Feature Positive (FP) groups, on N+A sessions, the offset of 
each of the 15-sec cue light presentations was followed by sucrose presentation. On water 
sessions, no sucrose was delivered following the offset of the cue light presentations. For the 
Feature Negative (FN) groups, the reverse training occurred. That is, sucrose was presented 
following light presentations on water sessions, but not on N+A sessions. There were 10 cue 
light presentations (conditioned stimulus, CS) during each session. The onset of the first CS 
presentation varied from 45-75 s, and the inter-trial intervals (time from CS offset to the next 
CS onset) ranged from 30-105 s. Water and N+A training days varied on a double 
alternation schedule (W, W, N+A, N+A…). The training sessions for both groups continued 
until the following acquisition criteria were met for both the first and the average 
discrimination score: For FP rats, the average of the discrimination score from the preceding 
two N+A sessions had to be ≥150% of the average of the discrimination scores from the 
preceding two water sessions. The converse was true for the FN rats. Testing began once 
these criteria were met.
Testing—Individual test sessions were 2 min in duration (following the 10 min delay), with 
1 light presentation that was followed by sucrose. For test sessions, onset of light 
presentation was randomized and varied from 45-105 seconds into the 2 minute test period. 
For Experiments 1 and 2, cumulative dosing procedures were used as we describe in 
(Besheer et al. 2012; 4 separate tests conducted in succession such that testing of the stated 
dose curve completed in ~48 min). For Experiment 3, single test sessions were used. Test 
sessions were interspersed with training sessions and if a rat did not meet the criteria for 
testing (i.e., acquisition criteria above), the rat remained in the home cage on that day. For all 
other experiments, testing occurred in a repeated measures (RM) design with all rats 
receiving all treatments in a randomized order.
Experiment 1. Characterization of the N+Alcohol compound cue under FP and FN 
conditions: Once acquisition criteria were met, rats in both groups (FP n=11, FN n=9) were 
tested on a cumulative N+A curve (0.1N+0.1A, 0.2N+0.3A, 0.4N+1A, 0.8N+1.7A mg/kg
+g/kg, IG) to determine whether goal-tracking behavior was under the control of the 
interoceptive effects of the N+A drug state (i.e., confirm stimulus control). Following this 
test, sensitivity to nicotine alone (0.1, 0.2, 0.4, 0.8 mg/kg, IG), and then alcohol alone (0.1, 
0.3, 1, 1.7 g/kg, IG) was assessed using the same cumulative dosing testing procedures.
Experiment 2. Effects of partial activation of α4β2 nAChR in the absence of the 
compound cue: In order to determine whether VAR has interoceptive effects similar to the 
N+A compound cue, rats in both groups (same rats from Experiment 1; FP n=11, FN n=9) 
received VAR alone (0, 1, 3 mg/kg, IP), 20 min prior to chamber placement (no IG 
treatment) for a 2-min test.
Experiment 3. Effects of partial activation of α4β2 nicotinic acetylcholine receptor 
(nAChR) on sensitivity to the N+A compound cue and its components: To determine 
whether VAR alters sensitivity to the N+A compound cue, another group N+A- trained rats 
(FP n=8, FN n=7) received VAR (0, 1 mg/kg, IP) 20 minutes prior to a cumulative N+A test 
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(0.1N+0.1A, 0.2N+0.3A, 0.4N+1A, 0.8N+1.7A mg/kg+g/kg, IG), nicotine alone (0.1, 0.2, 
0.4, 0.8 mg/kg, IG), and alcohol alone (0.1, 0.3, 1, 1.7 g/kg, IG).
Blood Alcohol Concentration (BAC) Analysis: To assess whether adding nicotine to the 
alcohol solution affected BAC, on a non-training day, a subset of animals from Experiment 1 
(n=12; FP n=6, FN n=6) were pretreated with the N+A training dose (0.4 mg/kg nicotine 
+ 1.0 g/kg alcohol; IG) or alcohol alone (1 g/kg, IG). Tail blood was collected 10 and 30 
minutes later for BAC analysis. Plasma supernatant (5 μl) was analyzed for alcohol content 
using an Analox Alcohol Analyser (Model AM1, Analox Instruments USA Inc., Lunenburg, 
MA).
Drugs—Alcohol (95%, Pharmaco-AAPER, Shelbyville, KY) was diluted in distilled water 
to a concentration of 20% (v/v). For N+A treatments, nicotine tartrate (Sigma-Aldrich, St. 
Louis, MO) was dissolved in 20% alcohol. When nicotine was administered alone, it was 
dissolved in distilled water. All nicotine doses are expressed in base form and the pH of 
solutions was not adjusted as is common in studies using oral routes of nicotine 
administration (Alsharari et al. 2014; Aschhoff et al. 2000; Wilking et al. 2012). The N+A 
solution was administered IG, with volumes varied by weight to obtain the desired doses. 
Nicotine and alcohol doses were based on previous drug discrimination literature for each 
alone and in combination (Besheer et al. 2012; Charntikov et al. 2014; Ford et al. 2012; 
Gauvin and Holloway 1993; Pittenger and Bevins 2013; Pittenger et al. 2015; Polewan et al. 
2013; Quertemont and Grant 2002; 2004; Quertemont et al. 2003; Troisi et al. 2013). 
Varenicline (Abcam Pharmaceuticals) dose and pretreatment interval were chosen based on 
previous studies (Ginsburg and Lamb 2013; Randall et al. 2015). VAR was dissolved in 
saline and injected intraperitoneally (IP) at a volume of 1 ml/kg.
Statistical Analyses—Given that the FP and FN groups have opposite training 
experience, these groups were analyzed separately. The number of head entries into the 
liquid receptacle was recorded in 15-s intervals throughout the training and testing sessions. 
The discrimination score was calculated by subtracting the number of head entries that 
occurred in the 15 sec before light onset (i.e., pre-CS) from the head entries that occurred 
during the 15-s light CS (Besheer et al. 2012; Murray et al. 2007; Palmatier et al. 2004; 
Palmatier et al. 2005). The first head entry discrimination score (i.e. prior to feedback from 
sucrose delivery) was used as the primary dependent variable. In order to provide a measure 
of general head entry activity (in addition to cue-related activity), head entry rate (head 
entries/min) was analyzed for all sessions. Locomotor rate (beam breaks/min) was analyzed 
for the entire session and served as a measure of non-specific motor activity. For acquisition 
training (Experiment 1), two-way repeated measures (RM) analysis of variance (ANOVA) 
was used to analyze discrimination scores between N+A and water sessions. For the 
cumulative substitution tests, to confirm that the training dose induced similar discrimination 
performance to that of training sessions, a paired samples t-test was used to compare the 
discrimination score from the training dose (0.4N+1A) at the test to the average of the 2 N
+A sessions prior to testing (i.e., baseline). RM ANOVA was used to assess differences in 
discrimination score across each dose in the curve, with post-hoc analysis (Tukey) used to 
compare doses to the training dose within the curve. For locomotor rate and head entry rate, 
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RM ANOVA was used to assess differences across each dose in the curve with post-hoc 
analysis (Tukey) used to compare doses to the lowest (i.e., subthreshold) dose. Full 
substitution for the N+A training dose was determined when the discrimination score at a 
given dose did not differ from discrimination score at the N+A training dose in the curve. 
For VAR discrete dosing (Experiment 2), RM ANOVA was used to assess effects of VAR 
doses on discrimination score. For Experiment 3, two-way RM ANOVA with VAR dose and 
cumulative dose as factors was used to assess effects of VAR pretreatment on each group 
separately (FP or FN). Similar to Experiment 1, paired-samples t-test was used to determine 
whether the training dose in the curve following saline treatment was significantly different 
from the preceding baseline sessions. For BAC analysis, paired samples t-test was used to 
determine whether N+A (0.4N+1.0A) was different from alcohol alone (1 g/kg) at either 
time point. The area under the curve was also determined and compared by t-test. 
Significance was declared at p ≤ 0.05.
Results
Experiment 1. Characterization of the N+A compound cue under FP and FN conditions
Acquisition of discrimination behavior
FP group: Acquisition of the discrimination in the FP group is illustrated in Figure 1A. 
Two-way RM ANOVA using treatment and session as factors found that discrimination 
scores were affected by treatment condition (F[1,10] = 30.435, p < 0.01), session (F[9,90] = 
4.489, p < 0.01) and there was a treatment by session interaction in discrimination score 
(F[9,90] = 5.438, p < 0.01). By the fifth session (i.e., 10 training days), rats showed 
significantly greater discrimination scores on N+A sessions compared to water sessions 
(Figure 1A), indicating acquisition of the discrimination. There was a significant effect of 
session (F[9,90] = 2.461, p < 0.05) and a day by treatment interaction (F[9,90] = 2.556, p < 
0.01) on locomotor rate, with higher locomotor rates on N+A compared to water sessions 
(Figure 1B). Furthermore, there was a main effect of session (F[9,90] = 14.093, p < 0.01) 
and a session by treatment interaction (F[9,90] = 6.964, p < 0.01), with higher head entry 
rates on N+A than water on sessions 2-10 (Table 1). Only the first ten sessions are shown for 
acquisition as all rats achieved testing criteria within that time.
FN Group: Acquisition of the discrimination in the FN group is illustrated in Figure 1C. 
Two- way RM ANOVA using treatment and session as factors showed a significant effect of 
treatment (F[1,8] = 12.535, p < 0.01), session (F[9,72] = 8.784, p < 0.01) and a treatment by 
session interaction (F[9,72] = 3.904, p < 0.01). By the sixth session, rats showed 
significantly greater discrimination scores on water compared to N+A sessions (Figure 1C), 
indicating acquisition of the discrimination. As shown in Figure 1D, locomotor rate was not 
different between N+A and water sessions. In addition, ANOVA showed a significant effect 
of session (F[9,72] = 7.979, p < 0.01) and a session by treatment interaction (F[9,72] = 
4.031, p < 0.01), with greater head entry rate on water than N+A sessions on all sessions 
(Table 1). Only the first ten sessions are shown as all rats achieved testing criteria within that 
time.
Randall et al. Page 6
Psychopharmacology (Berl). Author manuscript; available in PMC 2017 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Confirmation of Stimulus Control and expression of sensitivity to components
FP Group
N+A compound substitution: As shown in Figure 2A, during the substitution test, the 
discrimination score of the training dose (0.4N+1.0A) did not differ from baseline (i.e., BL, 
left of axis break), indicating appropriate performance and sensitivity to the training dose 
under the cumulative dosing procedures. The discrimination score was significantly affected 
by N+A dose combination (F[3,30] = 6.512, p < 0.01), with all doses substituting for the 
training dose except the sub-threshold dose combination (0.1N+0.1A; p<0.05), confirming N
+A stimulus control. Locomotor rate was not significantly affected by N+A dose (Fig. 2B). 
ANOVA showed that head entry rate significantly increased as N+A dose increased (F[3,30] 
= 3.46, p < 0.05), with higher head entry rate following the training dose than the lowest 
dose (Table 2).
Nicotine Substitution: As shown in Figure 2C, the discrimination score following the 
nicotine component of the training dose (0.4 mg/kg nicotine) was significantly higher than 
the N+A baseline (p<0.05), suggesting that the nicotine component may act as a more 
salient cue than the N+A training dose. Analysis of the discrimination score showed an 
inverted u-shaped function (F[3,30] = 11.630, p < 0.01), with each nicotine dose 
significantly lower than the training dose component (p<0.05). Nicotine significantly 
increased locomotor rate (F[3,30] = 5.915, p < 0.05), with 0.4 and 0.8 mg/kg nicotine 
significantly higher than the lowest dose (0.1 mg/kg). Similarly, head entry rate significantly 
increased as the nicotine dose increased (F[3,30] = 6.14, p < 0.01), with higher head entry 
rates at 0.4 mg/kg nicotine than the lowest dose (Table 2).
FP Alcohol Substitution: Figure 2E shows that the discrimination score for the alcohol 
component of the training dose (1.0 g/kg alcohol) was significantly lower than the N+A 
baseline, suggesting that alcohol alone does not substitute for the N+A training dose. 
However, there was a significant increase in discrimination score with increasing alcohol 
doses (F[3,27] = 6.043, p < 0.05), with a significantly lower discrimination score at the 0.1 
mg/kg dose relative to the alcohol component (1 g/kg) of the N+A training dose. There were 
no significant effects of alcohol dose on locomotor rate (Figure 2F) or head entry rate (Table 
2).
FN Group
N+A compound substitution: As shown in Figure 3A, the discrimination score following 
the training dose (0.4N+1A) did not differ from baseline (left of axis break). The 
discrimination score decreased as the N+A dose combination increased (F[3,24] = 6.02, p < 
0.05), confirming stimulus control. The 0.1N+0.1A and 0.2N+0.3A doses did not substitute 
for the N+A training dose, showing significantly higher discrimination scores than the 
training dose. Locomotor rate and head entry rate were not affected by N+A dose (Figure 
3B, Table 2).
Nicotine Substitution: As shown in Figure 3C, the discrimination score following the 
nicotine component (0.4 mg/kg) of the compound training dose was significantly higher than 
the N+A baseline (p < 0.05) suggesting that the nicotine component alone does not 
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substitute for the N+A training dose under these conditions. As shown in Figure 3C, there 
were no significant effects of nicotine dose on discrimination score, locomotor rate or head 
entry rate (Figure 3D, Table 2).
Alcohol Substitution: Figure 3E shows that the discrimination score following the alcohol 
component (1.0 g/kg) of the compound training dose was significantly higher than the N+A 
baseline (p < 0.05), suggesting that the alcohol component alone does not substitute for the 
N+A training dose. There was no significant effect of alcohol dose on discrimination score 
(Figure 3E), locomotor rate or head entry rate (Figure 3F, Table 2).
Experiment 2. Effects of partial activation of α4β2 nAChR in the absence of the compound 
cue
FP Group—As shown in Figure 4A, VAR administered alone (in the absence of the N+A 
compound cue) increased discrimination score (F[2,14] = 3.74, p < 0.05), with a higher 
discrimination score at 1.0 mg/kg VAR relative to saline (p<0.05). Furthermore, the 
discrimination score following 1 mg/kg VAR was not different from the N+A baseline (left 
of axis break) indicating that VAR had interoceptive effects similar to the N+A training dose 
(i.e., full substitution). In addition, as shown in Figure 4B, locomotor rate was significantly 
increased by VAR alone (F[2,14] = 3.99, p < 0.05) at the 1.0 mg/kg dose. There were no 
significant effects of VAR alone on head entry rate (Table 2).
FN Group—VAR administered alone decreased discrimination score (F[2,10] = 10.882, p < 
0.01), with significant decreases at both doses relative to saline (p<0.05; Figure 4C). 
Moreover, the discrimination score following both doses was not different from N+A 
baseline (i.e., full substitution), again indicating that VAR had interoceptive effects similar to 
the N+A compound. VAR did not affect locomotor rate (Figure 4D) or head entry rate (Table 
2).
Experiment 3. Effects of partial activation of α4β2 nicotinic acetylcholine receptor (nAChR) 
on sensitivity to the N+A compound cue and its components
FP Group
Effects of VAR on N+A substitution curve: Following saline pretreatment, the 
discrimination score at the N+A training dose was not different from the N+A baseline 
(Figure 5A), similar to the findings from Experiment 1 (Figure 2A). As shown in Figure 5A, 
RM ANOVA found a significant main effect of N+A dose on discrimination score (F[3,24] = 
3.880, p < 0.05) and VAR dose (F[1,24] = 6.497, p < 0.05), however there was no VAR by N
+A dose interaction. Given that Experiment 2 found that this dose of VAR (1 mg/kg) alone 
produced interoceptive effects similar to the N+A compound cue, planned comparisons were 
conducted to examine whether VAR potentiated sensitivity to N+A. Indeed, at the lowest N
+A dose combination (0.1N+0.1A) the discrimination score was significantly higher 
following VAR relative to saline pretreatment (p < 0.05). In addition, as shown in Figure 5B, 
there was a significant main effect of VAR dose (F[1,24] = 5.196, p < 0.05), N+A dose 
(F[3,24] = 4.278, p < 0.05), and a significant VAR by N+A dose interaction on locomotor 
rate (F[3,24]= 3.270, p < 0.05), with increased locomotor rate following VAR treatment 
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relative to saline at the 0.1N+0.1A and 0.2N+0.3A dose combinations (p < 0.05). Head entry 
rate was not affected by VAR (Table 2).
Effects of VAR on nicotine substitution curve: Following saline, the discrimination score 
at the nicotine component (0.4 mg/kg) of the N+A training dose was significantly higher 
than the N+A baseline (p < 0.05; Figure 5C), consistent with the data pattern observed in 
Figure 2C. As shown in Figure 5C, two-way RM ANOVA found a significant main effect of 
nicotine dose (F[3,21] = 5.423, p < 0.05) and a VAR by nicotine dose interaction (F[3,21] = 
4.051, p < 0.05) on discrimination score, with significantly higher discrimination scores than 
saline at the lowest nicotine dose (0.1 mg/kg), but significantly lower at the training dose 
component (0.4 mg/kg) compared to saline (p < 0.05). These findings indicate that VAR 
enhanced the effects of the lower nicotine doses and blocked the effects of the higher 
nicotine doses. There was a significant main effect of VAR dose (F[1,21] = 7.842, p < 0.05), 
nicotine dose (F[3,21] = 4.431, p < 0.05) and interaction (F[3,21] = 9.994, p < 0.05) on 
locomotor rate, with increased locomotor rate at the lowest nicotine dose and decreased 
locomotor rate at the training and highest nicotine dose relative to vehicle (p < 0.05; Figure 
5D). VAR did not alter head entry rate (Table 2).
Effects of VAR on alcohol substitution curve: Following saline, the discrimination score 
following 1 g/kg alcohol was not significantly different from N+A baseline (Figure 5E). 
VAR had no effects on alcohol discrimination score (Figure 5E). Therefore, given that under 
saline conditions alcohol alone had effects similar to the N+A training dose, VAR did not 
alter sensitivity to the alcohol component alone. Locomotor rate (Figure 5F) and head entry 
rate (Table 2) were also not affected by VAR.
FN Group
Effects of VAR on substitution curves: Under saline conditions, discrimination score 
following the N+A training dose was not different from N+A baseline, again confirming 
stimulus control (Table 4). However, nicotine and alcohol alone were significantly higher 
than the N+A baselines (p < 0.05, Table 4). There were no significant effects of VAR on 
discrimination scores, locomotor rate or head rate at any dose combination of N+A, nicotine 
alone or alcohol alone, suggesting that VAR does not affect processes related to the FN 
discrimination (Table 2, 4).
Blood Alcohol Concentration (BAC) Analysis
There was no significant difference in BAC or area under the curve between rats treated with 
N+A or alcohol alone at either time point (Table 3), suggesting that under these conditions 
and time points that are relevant for the present work, addition of nicotine to the alcohol 
solution does not interfere with alcohol blood levels.
Discussion
Nicotine and alcohol co-abuse is a complex and costly public health issue. Understanding 
this problem from a behavioral perspective is crucial to developing more effective 
treatments. To this end, the current experiments have numerous important findings. First, 
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oral administration of N+A effectively served as an interoceptive compound cue as 
evidenced by modulation of discriminated goal-tracking behavior. Second, this N+A drug 
state represents a unique interoceptive cue from each of the components (i.e., nicotine or 
alcohol alone). Third, the nicotinic partial agonist VAR produces interoceptive effects 
similar to the N+A compound cue as demonstrated by substitution for the N+A compound 
cue when administered alone.
A unique feature of the current experiments is that the nicotine was delivered orally as a 
cocktail with the alcohol. To our knowledge, this is the first drug discrimination study to 
train a N+A compound cue by an oral route of administration. The selection of this route of 
administration was related to feasibility given that in our previous work, alcohol is 
administered IG (Besheer et al. 2012; Jaramillo et al. 2015; Randall et al. 2015) and previous 
drug discrimination work has shown that nicotine administered IG shows stimulus 
equivalence to nicotine administered IP or SC (Craft and Howard 1988). While there is 
evidence that oral coadministration of nicotine (≥0.5 mg/kg) and alcohol (4 g/kg) 
significantly decreases BAC in adult rats (Parnell et al. 2006), here, we show that under the 
time parameters and doses relevant to the present work, IG administration of both does not 
affect BAC (Table 3). Therefore, differences in the relative contribution of each component 
to the N+A drug state is likely not related to nicotine interfering with alcohol levels, 
however, it will be important to determine if under our training conditions nicotine levels are 
affected by alcohol.
The initial series of experiments demonstrated that a N+A compound interoceptive cue 
could be trained to modulate behavior using a Pavlovian drug discrimination procedure. That 
is, the N+A drug cue effectively engendered goal-tracking behavior in rats with FP training 
(Fig 1A) and withholding of goal-tracking behavior in rats with FN training (Fig 1C). 
Interestingly, the FP discrimination was acquired slightly faster and less variable than the FN 
discrimination, consistent with previous suggestions that a FP discrimination is easier to 
learn than a FN discrimination (Hearst 1987). Furthermore, locomotor rate was generally 
dependent on training condition. That is, in the FP group, locomotor rate was greater on N
+A relative to water sessions, whereas in the FN group locomotor rate did not differ between 
N+A and water sessions. A possible explanation is that the combination of the excitatory 
properties of the cue light CS in the FP group, coupled with the psychomotor stimulating 
properties of nicotine results in an overall locomotor enhancement that is not observed in the 
FN group due to the inhibitory relationship of the cue light CS. Indeed, previous studies 
suggest that the inhibitory relationship between the drug state and CS in a FN association 
competes with the psychomotor stimulant properties of test compounds such as 
methamphetamine or cocaine, causing an overall decrease in activity (Pinkston and Branch 
2003; Reichel et al. 2007). In addition, it is unlikely that sensitization to the locomotor 
effects of nicotine is a factor as locomotor rate in the FN group was not affected.
Characterization of each component of the N+A compound cue showed that in the FP group, 
discrimination scores were potentiated following the nicotine component of the training dose 
(0.4 mg/kg) relative to the N+A training dose baseline, whereas discrimination scores 
following the alcohol component of the training dose (1 g/kg) failed to reach the N+A 
baseline level. This suggests that the nicotine component may play a greater role in the 
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interoceptive effects of the N+A compound cue (i.e., nicotine effects may “overshadow” the 
alcohol effects). This suggestion is consistent with work showing that nicotine evokes 
greater control over behavior than alcohol in rats trained to discriminate a N+A compound 
cue (Troisi et al. 2013), but in contrast to work showing that alcohol “overshadows” the 
nicotine component in mice trained to discrimination a N+A compound cue (Ford et al. 
2012). Moreover, the lack of alcohol substitution for the N+A training dose is consistent 
with other work using a similar N+A training dose to the present study (administered IP), 
but in that study nicotine failed to fully substitute for the N+A training dose which is in 
contrast to our results (Gauvin and Holloway 1993). This array of findings highlights the 
complex nature of the N+A interoceptive cue and differences across studies could be 
attributed to variables such as strain or species - which may have differential sensitivity to 
nicotine and/or alcohol, behavioral training procedures, route of drug administration - which 
may be related to differences in ascending/descending limbs of drug levels, and importantly, 
the N+A training dose combinations used.
An important feature of the current experiments is the use of both FP and FN training 
conditions. Given that these drug-conditioned associations likely rely on different 
behavioral/neural mechanisms, these two training procedures allow for a multidimensional 
assessment of the ability of the drug state to excite or inhibit behavior. For example, in 
contrast to the data pattern in the FP group, in the FN group, nicotine did not substitute for 
the N+A training dose. Further, in the FN group, alcohol also did not substitute which is 
consistent with the findings of the FP group (Fig. 2 and 3). This would suggest that the cue 
light CS is generally excitatory in both the FP and FN groups. The exception is when the CS 
is paired with the specific training condition (N+A) in the FN group, upon which inhibitory 
processes outweigh the excitatory influence of the CS. Together, these findings suggest that 
the N+A compound represents a unique interoceptive cue from either component on its own. 
This assertion is supported by another study in which extinction of the components of a N
+A interoceptive cue did not extinguish discrimination following re-exposure to the N+A 
cue (Troisi et al. 2013).
Considering the growing interest in using VAR for the treatment of AUDs, it is important to 
assess whether sensitivity to the N+A compound cue or its components is altered by VAR 
pretreatment. In both the FP and FN groups, VAR fully substituted for the N+A compound 
cue (i.e., VAR has stimulus effects similar to the N+A compound cue; Figure 4). These 
results are consistent with previous nicotine studies that show VAR substitutes for nicotine 
and generalizes to nicotine if extinguished using a Pavlovian goal-tracking procedure 
(Reichel et al. 2010), and partially substitutes for nicotine in operant drug discrimination 
studies (LeSage et al. 2009; Paterson et al. 2010). Interestingly, previous operant drug 
discrimination work from our lab has shown that VAR does not substitute for alcohol 
(Randall et al. 2015). This finding lends further support to the idea that the nicotine 
component may play a greater role in the N+A cue. Lastly, although there was a significant 
VAR-induced increase in locomotor rate in the FP group, there were no significant effects on 
head entry rate in either group, demonstrating that behavior specifically related to the light 
cue was enhanced.
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Consistent with VAR having N+A-like effects, VAR enhanced sensitivity to the lowest N+A 
dose (0.1N+0.1A) in the FP group (Figure 5A). Interestingly, when VAR was administered 
with nicotine alone, discrimination scores were similar across all nicotine doses (i.e., 
potentiation at the lowest dose (0.1N) and suppressed at the training dose (0.4N) relative to 
saline pretreatment; Figure 5C). Given the partial agonist properties of VAR, this outcome is 
not entirely unexpected. VAR induces a reduced but sustained level of intrinsic activity at 
nAChRs compared to nicotine while also preventing nicotine from binding and producing 
greater intrinsic effects (Coe et al. 2005). In contrast to the FP group, in the FN group, VAR 
pretreatment did not affect sensitivity to the N+A compound or the nicotine or alcohol 
components (Table 4). This finding suggests that VAR may not affect behavioral 
mechanisms related to the FN association. That is, VAR may only exert effects on excitatory 
processes related to the FP association, as opposed to the inhibitory processes active during 
that FN association.
Taken together, these VAR findings point to a possible convergent pathway by which 
nAChRs (specifically α4β2) modulate sensitivity to a N+A drug state. In addition to 
nicotine- induced activity at nAChRs, alcohol can also affect nAChRs activity. For example, 
alcohol has been shown to enhance the binding affinity of acetylcholine for the nAChR (Ei-
Fakahany et al. 1983; Forman et al. 1989). Moreover, alcohol can directly modulate nAChR 
ligand-gated cation channel activity (K+/Na+), increasing duration of the open state (Wu et 
al. 1994). Additionally, α4β2 receptors are highly expressed in nucleus accumbens core and 
medial prefrontal cortex (Klink et al. 2001; Zoli et al. 2002), brain regions important for 
goal-directed, reinforcement- seeking behavior (see Everitt et al., 1999 for review). These 
receptors also play an important role in modulating the reinforcing properties of nicotine 
(Crawley et al. 1997; Tapper et al. 2004) and potentially alcohol, (see Chatterjee and 
Bartlett, 2010 for review). These effects are thought to be due, in part, to nAChR-mediated 
effects on mesolimbic dopamine release. Indeed, both alcohol and nicotine alone increase 
forebrain dopamine (DA) release (Di Chiara and Imperato 1985; Ericson et al. 2009; Tizabi 
et al. 2002) and N+A increases DA release to a greater degree than each alone (Doyon et al. 
2013; Tizabi et al. 2007). It will be interesting for future experiments to investigate brain 
regional involvement of nAChRs, the potential role of DA, and the neural circuitry 
underlying sensitivity to a N+A drug state.
An important aspect of understanding drug use and relapse are the numerous cues, both 
external and internal (i.e., interoceptive), with which drug use and drug effects become 
associated. As such, these conditioned cues can come to gain motivational value such that 
they can play an important role in promoting drug taking and seeking behaviors. Therefore, 
examining and characterizing interoceptive drug cues are critical to broadening our 
understanding of addiction-related processes. In summary, the nicotine+alcohol compound 
cue represents a salient stimulus, that once associated with reward (i.e., sucrose) can come to 
entrain discriminated goal-tracking behavior. This work represents the first study to 
characterize the N+A compound cue utilizing a Pavlovian drug discrimination procedure. In 
addition, partial activation of nAChRs using VAR produces behavior similar to that of the N
+A compound cue, suggesting that VAR produces interoceptive effects similar to that of the 
N+A cue. Taken together, it will be important for future work to consider how interoceptive 
effects of a N+A compound cue (or nicotine and alcohol alone) may influence ongoing co-
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use as measured by self-administration (or self-administration of each alone), relapse-like 
behavior or the effects of extinguishing the N+A cue or its components on these behaviors.
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Figure 1. 
Acquisition of nicotine+alcohol discrimination. Mean(±S.E.M.) discrimination score (head 
entries during the 15-s light CS minus head entries during 15 seconds before light onset, A) 
and locomotor rate (beam breaks per minute, B) in the Feature Positive group. 
Mean(±S.E.M.) discrimination score (C) and locomotor rate (D) in the feature negative 
group. *- denotes significant differences between N+A and water session (p < 0.05).
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Figure 2. 
Substitution curves for the Feature Positive group. Mean(±S.E.M.) discrimination score 
(head entries during the 15-s light CS minus head entries during 15 seconds before light 
onset, A) and locomotor rate (beam breaks per minute, B) for N+A substitution test. 
Mean(±S.E.M.) discrimination score (C) and locomotor rate (D) for nicotine only 
substitution test. Mean(±S.E.M.) discrimination score (E) and locomotor rate (F) for the 
alcohol only substitution test. *-denotes significant difference from training dose in the 
curve (p < 0.05). +-denotes significant difference from N+A baseline (p < 0.05). ˆ- denotes 
significant difference from lowest dose for locomotor rate (p < 0.05)
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Figure 3. 
Substitution curves for the Feature Negative group. Mean(±S.E.M.) discrimination score 
(head entries during the 15-s light CS minus head entries during 15 seconds before light 
onset, A) and locomotor rate (beam breaks per minute, B) for N+A substitution test. 
Mean(±S.E.M.) discrimination score (C) and locomotor rate (D) on the nicotine only 
substitution test. Mean(±S.E.M.) discrimination score (E) and locomotor rate (F) on the 
alcohol only substitution test. *-denotes significant difference from training dose in the 
curve. +-denotes significant difference from N+A baseline.
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Figure 4. 
Effects of varenicline alone on rats trained to discriminate N+A. Mean (±S.E.M.) 
discrimination score (head entries during the 15-s light CS minus head entries during 15 
seconds before light onset, A) and locomotor rate (beam breaks per minute, B) following 
varenicline injection in the feature positive group. Mean(±S.E.M.) discrimination score (C) 
and locomotor rate (D) following varenicline injection in the feature negative group. *-
denotes significantly different from saline (p < 0.05). +-denotes significantly different from 
N+A baseline (p < 0.05).
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Figure 5. 
Effects of varenicline in substitution curves for the Feature Positive group. Mean(+S.E.M.) 
discrimination score (head entries during the 15-s light CS minus head entries during 15 
seconds before light onset, A) and locomotor rate (beam breaks per minute, B) for the N+A 
substitution test following varenicline (1 mg/kg) or saline pretreatment. Mean(±S.E.M.) 
discrimination score (C) and locomotor rate (D) for the nicotine only substitution test 
following varenicline or saline pretreatment. Mean(±S.E.M.) discrimination score (E) and 
locomotor rate (F) of the alcohol only substitution test following varenicline or saline 
pretreatment. *-denotes significant difference between varenicline and saline pretreatments 
(p < 0.05). +-denotes significant difference between training dose in the curve and N+A 
baseline (p < 0.05). #-denotes significant difference with planned comparison between 
varenicline and saline pretreatments (p < 0.05).
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Table 3
Mean (±S.E.M.) mg/dl blood alcohol concentration (BAC) and area under the curve (AUC) following N+A 
(0.4 mg/kg N + 1 g/kg A) or alcohol alone (1 g/kg), IG.
BAC (mg/dl) 10 min 30 min
 0.4N+1A 28.28±2.59 41.21±2.90
 1A 27.48±4.33 47.03±6.26
AUC
 0.4N+1A 695.00±80.14
 1A 745.16+74.10
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